Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.9% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
0
users have commented on this narrative
38
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Gildan Activewear
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Basic Apparel And US Cotton Efficiency Will Drive Future Success
Key Takeaways Gildan's cost-efficient, ethically focused manufacturing and value-oriented products provide strong competitive advantages and support growth amid shifting consumer and regulatory trends. Strategic brand expansion, automation investment, and competitor weakness drive higher-margin growth and increased market share in key apparel segments.
View narrative
CA$90.03
FV
n/a
intrinsic discount
4.66%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
Updated
narrative
LiveOne
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Fortune 500 Deal And AI Curation Will Expand Digital Entertainment
Key Takeaways Expanding B2B partnerships, proprietary tech, and exclusive content is driving scalability, operational efficiency, and diverse, high-margin revenue opportunities. Enhanced balance sheet and innovative event monetization position the company to capitalize on digital entertainment's global growth and shifting consumer models.
View narrative
US$2.35
FV
72.4% undervalued
intrinsic discount
12.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
about 10 hours ago
author updated this narrative
Thyrocare Technologies
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Franchise Expansion And PharmEasy Partnerships Will Secure Future Success
Key Takeaways Rapid network expansion and broader service offerings are increasing test volumes, driving sustained revenue and margin growth through operating leverage and higher-value tests. Focus on quality accreditation, technology, and digital partnerships strengthens market position, improves efficiency, and supports ongoing growth in demand and profitability.
View narrative
₹1.36k
FV
2.3% overvalued
intrinsic discount
19.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
1 day ago
author updated this narrative
Atlas Energy Solutions
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Permian Shale Trends Will Secure A Resilient Logistics Future
Key Takeaways Shrinking competition and integrated logistics are boosting Atlas' pricing power, asset utilization, and long-term contract stability with Permian energy customers. Diversification into power and tech sectors, combined with rising sand intensity, supports predictable, cyclicality-resistant revenue growth and expanding margins.
View narrative
US$15.55
FV
27.2% undervalued
intrinsic discount
2.93%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
31
users have followed this narrative
1 day ago
author updated this narrative
Roivant Sciences
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Key Takeaways Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas. Potential in-licensing and late-stage pipeline approvals could significantly enhance earnings and portfolio sales impact.
View narrative
US$17.00
FV
30.9% undervalued
intrinsic discount
148.75%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
17 days ago
author updated this narrative
Rani Therapeutics Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
RT-114 And Pill Technology Will Transform Obesity Treatments
Key Takeaways RaniPill technology and RT-114 partnership position Rani Therapeutics to capture significant market share and boost future revenue. Extensive patent portfolio and cost containment measures enhance protection, licensing opportunities, and improve net margins.
View narrative
US$7.75
FV
n/a
intrinsic discount
228.14%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
Updated
narrative
AMN Healthcare Services
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Aging US Population And Technology Will Reshape Healthcare Staffing
Key Takeaways Structural shifts toward flexible staffing and diversification into new service areas are strengthening the company's position, reducing risk, and driving sustainable revenue growth. Technology adoption and strategic acquisitions are improving operational efficiency and enhancing market share opportunities as industry consolidation accelerates.
View narrative
US$20.29
FV
8.0% undervalued
intrinsic discount
-2.64%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
Updated
narrative
LivaNova
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Aging Populations And China Expansion Will Drive Device Adoption
Key Takeaways Clinical innovation and regulatory momentum are expected to accelerate global adoption of LivaNova's therapies, unlocking new markets and strengthening pricing power and margins. Strategic focus on recurring revenue, service monetization, and operational efficiency should improve earnings quality and support the shift to higher-margin, innovative products.
View narrative
US$64.70
FV
16.3% undervalued
intrinsic discount
6.38%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
Updated
narrative
Advanced Energy Industries
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
AI Driven Data Centers And Semiconductors Will Spur Future Progress
Key Takeaways Growth in data center, AI, and semiconductor demand is driving strong adoption of new technology platforms, supporting future revenue and margin expansion. Strategic focus on higher-margin products, operational efficiencies, and investments in R&D and acquisitions is boosting earnings growth and market share diversification.
View narrative
US$147.20
FV
10.0% overvalued
intrinsic discount
8.41%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
1 day ago
author updated this narrative
Value any company in seconds
Popular companies